Plasma and urine beta-thromboglobulin concentration in patients with deep vein thrombosis [PDF]
Amihan M de Boer +5 more
openalex +1 more source
Aptamer‐Based Delivery Systems for VEGF and NGF Modulation in Ocular Therapies
Aptamer‐based delivery systems targeting NGF and VEGF hold significant potential for precise and sustained treatment of complex diseases affecting both the anterior and posterior segments of the eye. This review critically summarizes current strategies for NGF and VEGF delivery as well as VEGF sequestration, providing a clinical perspective on how ...
Nadine Best +5 more
wiley +1 more source
Venous infarct after sacrifice of single cortical vein during deep-brain stimulation surgery
Edvin Zekaj +4 more
openalex +1 more source
Thrombus Signal on T1-Weighted Black-Blood MR Predicts Outcomes of Catheter-Directed Thrombolysis in Acute Deep Vein Thrombosis [PDF]
Chen Huang +10 more
openalex +1 more source
The image shows a schematic form a nanobody‐conjugated theranostic prodrug (NBD) platform targeting tumor‐associated αvβ3 integrin. The NBD system integrates selective nanobody‐mediated tumor recognition, glutathione‐responsive disulfide cleavage for doxorubicin release, and aza‐BODIPY‐based near‐infrared fluorescence for real‐time imaging.
Sanu Karan +13 more
wiley +1 more source
This study presents the first entirely isogenic heart‐on‐chip, unifying cardiomyocytes, fibroblasts, and endothelial cells from a single iPSC source. The platform reveals a critical biological insight: the endothelium actively shields cardiac tissue from drug‐induced toxicity, challenging the predictive accuracy of conventional, avascular models for ...
Karine Tadevosyan +12 more
wiley +1 more source
Deep vein thrombosis and validation of the Caprini risk assessment model in Chinese orthopaedic trauma patients: a multi-center retrospective cohort study enrolling 34,893 patients [PDF]
Xian Zhang +3 more
openalex +1 more source
Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang +4 more
wiley +1 more source
This study demonstrates that ALY688, a drug mimicking the heart‐protective hormone adiponectin, reduces myocardial ischemia injury. ALY688 increases the production of extracellular vesicles, which carry protective cargo including adiponectin itself.
Jialing Tang +13 more
wiley +1 more source
Neutrophil CD14 is a driver and a therapeutic target for deep vein thrombosis. [PDF]
Pandey N +27 more
europepmc +1 more source

